Author

Sonia Martinez

Centro de Investigación Médica Aplicada

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:clinical cohort / trial· 1 Assay:CRISPR screen· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Ainhoa Goñi‐SalaverriiD· 1 shared Alicia G. Serrano· 1 shared Anna Rosaria de Vito· 1 shared Arantxa GonzáleziD· 1 shared Beatriz PelachoiD· 1 shared Belén Navarro‐GonzáleziD· 1 shared Brian J.P. HuntlyiD· 1 shared Carlota Cardona· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCell Biology

Ainhoa Goñi‐SalaverriORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Identification of epigenetic regulators of fibrotic transformation in cardiac fibroblasts through bulk and single-cell CRISPR screens

Laura Pilar Aguado‐Alvaro, Nerea Garitano, Wolfgang Esser‐Skala, Judith R. Sayers, Cynthia del Valle, Daniel Alameda, Julen Mendieta-Esteban, María Eréndira Calleja-Cervantes, Ainhoa Goñi‐Salaverri, Jon Zazpe, Anna Rosaria de Vito, Francesco P. Marchese, Diego Alignani, Juliana Cudini, Torsten Groß, , David Lara‐Astiaso

The paper identifies epigenetic regulators of fibrotic transformation in cardiac fibroblasts using bulk and single-cell CRISPR screens and shows KAT5 inhibition reduces fibrotic responses in human fibroblasts.

Nature Communications · Nov 26, 2025Peer-reviewedCell Biology

The tyrosine kinase inhibitor GNF-7 targets senescent cells through allosteric activation of GCN2.

Gema López-Pernas, Matilde Murga, Wareed Ahmed, Maria Häggblad, Elena Jiménez‐Ortega, Alicia G. Serrano, Carlota Cardona, Mario Lopez-Prieto, Samuele Fisicaro, Jorge Mota‐Pino, Belén Navarro‐González, Eduardo Zarzuela, Marta Elena Antón, Louise Lidemalm, Sonia Martinez, , Óscar Fernández-Capetillo

This study identifies GNF-7 as a senolytic drug that activates GCN2 to kill senescent cells, showing synergy with CDK4/6 inhibitors in preclinical models.

bioRxiv · Aug 29, 2025 · PreprintCancer Biology